InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,064.20
(
0.91%
)
US TECH 100
17,188.00
(
0.66%
)
Dow Jones
38,225.66
(
0.00%
)
Brent Oil
84.01
(
0.45%
)
Bitcoin
59,060.91
(
-0.10%
)
Post# of 251694
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119554
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jbog post# 243322

Friday, 07/29/2022 8:34:55 AM

Friday, July 29, 2022 8:34:55 AM

Post# of 251694
ENTA’s PR on EDP-235 phase-1/1b data:

https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-announces-positive-data-phase-1-clinical

Based on these positive safety and PK results, ENTA is advancing the 200mg qD and 400mg qD doses (without ritonavir boosting) to phase-2, which is expected to start in 4Q22.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up